The United States Department of Justice has formally charged two Indian nationals in a federal court in Florida for allegedly orchestrating a scheme to smuggle counterfeit Ozempic from China into the United States. One of the accused individuals, 33-year-old Swapnadip Roy, was successfully extradited from Italy and made his initial court appearance in the U.S. District Court in Tampa. Meanwhile, his alleged co-conspirator, 37-year-old Vicky Ramancha, remains at large. Both men face multiple federal counts, including conspiracy to smuggle and defraud the U.S., smuggling, and distributing counterfeit pharmaceuticals, carrying a combined maximum sentence of 71 years in prison upon conviction.
Modus Operandi and Supply Chain Operations:
According to court records, the defendants procured fake Ozempic products from unverified sources in China between July 2023 and April 2024. The operation utilized counterfeit packaging materials, instruction inserts, pen labels, and needles designed to deceive consumers into believing they were purchasing authentic medication. Prosecutors state that Ramancha negotiated deals with Florida-based businesses to distribute these unauthorized products at heavily discounted rates, while Roy allegedly resorted to intimidation and threats in late 2023 to manage the distribution network. The illicit enterprise persisted even after U.S. Food and Drug Administration (FDA) seizures and public safety warnings, with communications revealing that the conspirators planned to push forward with pending orders involving tens of thousands of units.
Rising Demand and Public Health Warnings:
This federal prosecution unfolds against the backdrop of soaring nationwide demand for GLP-1 medications like Ozempic, which are prescribed for diabetes management and increasingly utilized for weight loss. Recent data indicates a sharp escalation in usage, amplifying public health concerns surrounding illicit pharmaceutical supply chains. Assistant Attorney General A. Tysen Duva emphasized that counterfeit prescription drugs present severe risks to consumer health and market integrity. Legal authorities reiterate that the charges are allegations at this stage, and the defendants retain the presumption of innocence until proven guilty in a court of law.
